Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645420 | 1.00 | NPC1 (0.49) | NPC1RAB9AKMT2AMEN1ACHE | |
| SCHEMBL9347454 | 0.98 | KMT2A (0.48) | NPC1RAB9AKMT2AMEN1ACHE | |
| Hydrochloric Acid SCHEMBL4353079 | 0.98 | NPC1 (0.48) | NPC1RAB9AKMT2AMEN1ACHE | |
| Ammonia Solution, Strong SCHEMBL9633554 | 0.98 | NPC1 (0.48) | NPC1RAB9AKMT2AMEN1ACHE | |
| Hydrochloric Acid SCHEMBL28201693 | 0.96 | KMT2A (0.47) | NPC1RAB9AKMT2AMEN1ACHE | |
| Hydrochloric Acid SCHEMBL30688272 | 0.96 | CTSL (0.49) | NPC1RAB9AKMT2AMEN1ACHE | |
| Hydrochloric Acid SCHEMBL28869036 | 0.96 | CTSL (0.49) | NPC1RAB9AKMT2AMEN1ACHE | |
| SCHEMBL3506845 | 0.96 | NPC1 (0.49) | NPC1RAB9AKMT2AMEN1ACHE | |
| Bicarbonate SCHEMBL4200785 | 0.91 | ALDH1A1 (0.49) | NPC1RAB9AKMT2AMEN1ACHE | |
| SCHEMBL31742513 | 0.88 | ALDH1A1 (0.45) | NPC1RAB9AKMT2AMEN1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041736-A1 | FORMATION OF METHANE FROM SIDE PRODUCTS OF AN ALCOHOL CONVERSION PROCESS | BASF SE (DE) | 2026-02-26 | — | — | WO | claimed |
| WO-2026041750-A1 | AN ALCOHOL CONVERSION PROCESS | BASF SE (DE) | 2026-02-26 | — | — | WO | claimed |
| WO-2026041735-A1 | AN ALCOHOL CONVERSION PROCESS | BASF SE (DE) | 2026-02-26 | — | — | WO | claimed |
| WO-2025040770-A1 | AN ALCOHOL CONVERSION PROCESS | BASF SE (DE) | 2025-02-27 | — | — | WO | claimed |
| CN-119390586-A | Process for preparing aromatic polyamine mixtures | 巴斯夫欧洲公司 | 2025-02-07 | — | — | CN | claimed |
| CN-110143956-B | Tacrine-pyridothiophene compound and preparation method and application thereof | 中国药科大学 | 2022-07-29 | — | — | CN | claimed |
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-111704576-A | Synthesis method and application of axial chiral 9-aryl tetrahydroacridine | 菏泽学院 | 2020-09-25 | — | — | CN | claimed |
| US-20200271587-A1 | VISIBLE LIGHT-ACTIVATED DYES AND METHODS OF USE THEREOF | WILLIAM MARSH RICE UNIVERSITY | 2020-08-27 | — | — | US | claimed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| EP-0732926-B1 | PHARMACEUTICAL FORMULATION FOR PREVENTING OR PRE-TREATING POISONING BY ORGANOPHOSPHORIC CHOLINESTERASE INHIBITORS | LOHMANN THERAPIE SYST LTS (DE) | 2003-02-19 | — | — | EP | claimed |
| CN-1328451-A | Medicine for improving excretion capacity of bladder | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-26 | — | — | CN | claimed |
| US-6114347-A | Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 2000-09-05 | — | — | US | claimed |
| US-5939095-A | AT LEAST ONE PARASYMPATHOMIMETICALLY ACTIVE SUBSTANCE AND AT LEAST ONE PARASYMPATHOLYTICALLY ACTIVE SUBSTANCE | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1999-08-17 | — | — | US | claimed |
| CN-1222512-A | Improved amino acridine preparing process | UNIV BEIJING SCIENCE & TECH (CN) | 1999-07-14 | — | — | CN | claimed |
| EP-0732926-A1 | PHARMACEUTICAL FORMULATION FOR PREVENTING OR PRE-TREATING POISONING BY ORGANOPHOSPHORIC CHOLINESTERASE INHIBITORS | LTS LOHMANN Therapie-Systeme GmbH (DE) | 1996-09-25 | — | — | EP | claimed |
| EP-0732924-A1 | TRANSDERMAL THERAPEUTICAL SYSTEM FOR PREVENTING POISONING BY ORGANOPHOSPHORIC NUROTOXINS THAT CONSISTS OF A COMBINATION OF ACTIVE SUBSTANCES INCLUDING A PARASYMPATHOMIMETIC AND A PARASYMPATHOLYTIC AGENT | LTS LOHMANN Therapie-Systeme GmbH (DE) | 1996-09-25 | — | — | EP | claimed |
| EP-0375471-B1 | Use of 1,2,3,4-tetrahydro-acridines in the treatment of AIDS, and compounds | RECH NEWPHARM SOC CIV DE (FR) | 1996-04-10 | — | — | EP | claimed |
| WO-1995015755-A1 | TRANSDERMAL THERAPEUTICAL SYSTEM FOR PREVENTING POISONING BY ORGANOPHOSPHORIC NUROTOXINS THAT CONSISTS OF A COMBINATION OF ACTIVE SUBSTANCES INCLUDING A PARASYMPATHOMIMETIC AND A PARASYMPATHOLYTIC AGENT | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1995-06-15 | — | — | WO | claimed |
| WO-1995015756-A1 | PHARMACEUTICAL FORMULATION FOR PREVENTING OR PRE-TREATING POISONING BY ORGANOPHOSPHORIC CHOLINESTERASE INHIBITORS | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1995-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200271587-A1 | VISIBLE LIGHT-ACTIVATED DYES AND METHODS OF USE THEREOF | HCCS, CLTB, ALDH1A2 | NPC1 2031/4885RAB9A 509/4885KMT2A 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.